Designing nanomedicine for immuno-oncology

Wen Jiang, Christina A. Von Roemeling, Yuanxin Chen, Yaqing Qie, Xiujie Liu, Jianzhu Chen, Y S Betty Kim

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Two major obstacles facing cancer nanomedicine are the tendency of nanoparticles to be taken up by normal tissues and organs and the nanoparticles' inability to efficiently penetrate solid tumours. Although substantial efforts have been made to improve the intratumoural delivery of nanotherapeutics, many strategies have failed to produce meaningful clinical benefits. Recent advances in the field of immuno-oncology have led to drugs that boost the host's own immune system to fight cancer. In contrast to conventional therapies, which often target cancer cells, immunotherapies stimulate immune cells in ways that promote their recognition and the eradication of tumours. In this Perspective, we posit that this approach represents a new framework for cancer nanomedicine, and that immune-targeted nanomedicines could generate tumouricidal effects without the need to overcome the pathophysiological barriers that are intrinsic to the tumour microenvironment and that hinder nanoparticle delivery. The rational design of new immuno-oncology nanomedicines provides opportunities for developing the next generation of nanotherapeutics for cancer patients.

Original languageEnglish (US)
Article number0029
JournalNature Biomedical Engineering
Volume1
Issue number2
DOIs
StatePublished - Feb 10 2017

Fingerprint

Nanomedicine
Medical nanotechnology
Oncology
Tumors
Nanoparticles
Neoplasms
Immune system
Cells
Tissue
Tumor Microenvironment
Immunotherapy
Immune System
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Biomedical Engineering
  • Biotechnology
  • Bioengineering
  • Medicine (miscellaneous)
  • Computer Science Applications

Cite this

Jiang, W., Von Roemeling, C. A., Chen, Y., Qie, Y., Liu, X., Chen, J., & Kim, Y. S. B. (2017). Designing nanomedicine for immuno-oncology. Nature Biomedical Engineering, 1(2), [0029]. https://doi.org/10.1038/s41551-017-0029

Designing nanomedicine for immuno-oncology. / Jiang, Wen; Von Roemeling, Christina A.; Chen, Yuanxin; Qie, Yaqing; Liu, Xiujie; Chen, Jianzhu; Kim, Y S Betty.

In: Nature Biomedical Engineering, Vol. 1, No. 2, 0029, 10.02.2017.

Research output: Contribution to journalArticle

Jiang, W, Von Roemeling, CA, Chen, Y, Qie, Y, Liu, X, Chen, J & Kim, YSB 2017, 'Designing nanomedicine for immuno-oncology', Nature Biomedical Engineering, vol. 1, no. 2, 0029. https://doi.org/10.1038/s41551-017-0029
Jiang W, Von Roemeling CA, Chen Y, Qie Y, Liu X, Chen J et al. Designing nanomedicine for immuno-oncology. Nature Biomedical Engineering. 2017 Feb 10;1(2). 0029. https://doi.org/10.1038/s41551-017-0029
Jiang, Wen ; Von Roemeling, Christina A. ; Chen, Yuanxin ; Qie, Yaqing ; Liu, Xiujie ; Chen, Jianzhu ; Kim, Y S Betty. / Designing nanomedicine for immuno-oncology. In: Nature Biomedical Engineering. 2017 ; Vol. 1, No. 2.
@article{bf25c7768563403bbed46153b266452c,
title = "Designing nanomedicine for immuno-oncology",
abstract = "Two major obstacles facing cancer nanomedicine are the tendency of nanoparticles to be taken up by normal tissues and organs and the nanoparticles' inability to efficiently penetrate solid tumours. Although substantial efforts have been made to improve the intratumoural delivery of nanotherapeutics, many strategies have failed to produce meaningful clinical benefits. Recent advances in the field of immuno-oncology have led to drugs that boost the host's own immune system to fight cancer. In contrast to conventional therapies, which often target cancer cells, immunotherapies stimulate immune cells in ways that promote their recognition and the eradication of tumours. In this Perspective, we posit that this approach represents a new framework for cancer nanomedicine, and that immune-targeted nanomedicines could generate tumouricidal effects without the need to overcome the pathophysiological barriers that are intrinsic to the tumour microenvironment and that hinder nanoparticle delivery. The rational design of new immuno-oncology nanomedicines provides opportunities for developing the next generation of nanotherapeutics for cancer patients.",
author = "Wen Jiang and {Von Roemeling}, {Christina A.} and Yuanxin Chen and Yaqing Qie and Xiujie Liu and Jianzhu Chen and Kim, {Y S Betty}",
year = "2017",
month = "2",
day = "10",
doi = "10.1038/s41551-017-0029",
language = "English (US)",
volume = "1",
journal = "Nature Biomedical Engineering",
issn = "2157-846X",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Designing nanomedicine for immuno-oncology

AU - Jiang, Wen

AU - Von Roemeling, Christina A.

AU - Chen, Yuanxin

AU - Qie, Yaqing

AU - Liu, Xiujie

AU - Chen, Jianzhu

AU - Kim, Y S Betty

PY - 2017/2/10

Y1 - 2017/2/10

N2 - Two major obstacles facing cancer nanomedicine are the tendency of nanoparticles to be taken up by normal tissues and organs and the nanoparticles' inability to efficiently penetrate solid tumours. Although substantial efforts have been made to improve the intratumoural delivery of nanotherapeutics, many strategies have failed to produce meaningful clinical benefits. Recent advances in the field of immuno-oncology have led to drugs that boost the host's own immune system to fight cancer. In contrast to conventional therapies, which often target cancer cells, immunotherapies stimulate immune cells in ways that promote their recognition and the eradication of tumours. In this Perspective, we posit that this approach represents a new framework for cancer nanomedicine, and that immune-targeted nanomedicines could generate tumouricidal effects without the need to overcome the pathophysiological barriers that are intrinsic to the tumour microenvironment and that hinder nanoparticle delivery. The rational design of new immuno-oncology nanomedicines provides opportunities for developing the next generation of nanotherapeutics for cancer patients.

AB - Two major obstacles facing cancer nanomedicine are the tendency of nanoparticles to be taken up by normal tissues and organs and the nanoparticles' inability to efficiently penetrate solid tumours. Although substantial efforts have been made to improve the intratumoural delivery of nanotherapeutics, many strategies have failed to produce meaningful clinical benefits. Recent advances in the field of immuno-oncology have led to drugs that boost the host's own immune system to fight cancer. In contrast to conventional therapies, which often target cancer cells, immunotherapies stimulate immune cells in ways that promote their recognition and the eradication of tumours. In this Perspective, we posit that this approach represents a new framework for cancer nanomedicine, and that immune-targeted nanomedicines could generate tumouricidal effects without the need to overcome the pathophysiological barriers that are intrinsic to the tumour microenvironment and that hinder nanoparticle delivery. The rational design of new immuno-oncology nanomedicines provides opportunities for developing the next generation of nanotherapeutics for cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=85020455714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020455714&partnerID=8YFLogxK

U2 - 10.1038/s41551-017-0029

DO - 10.1038/s41551-017-0029

M3 - Article

AN - SCOPUS:85020455714

VL - 1

JO - Nature Biomedical Engineering

JF - Nature Biomedical Engineering

SN - 2157-846X

IS - 2

M1 - 0029

ER -